

## IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

<u> </u>			
International App	plication No.	:	PCT/EP03/02349
International Fili	ng Date	:	7 March 2003 (07.03.2003)
Priority Date(s)	Claimed	:	4 April 2002 (04.04.2002)
Applicant(s) (DO	)/EO/US)	:	Bertram CEZANNE et al
CORRESPOND	MINO-PYRROLII ING PIPERIDINE ENT OF THROMB	DERIVATIVE	NYL!-ACETAMIDE AND S AS FACTOR XA INHIBITORS FOR DISEASES
INFORMATIO	ON DISCLOSURE	STATEMEN	Γ UNDER 37 CFR §§ 1.56, 1.97 and 1.98
Commissioner f P.O. Box 1450 Alexandria, VA			
Sir:			•
This info	ormation disclosure ows:	statement is ma	de in accordance with 37 C.F.R. §§ 1.56, 1.97
Timing and Fee	<u>es</u>	,	
Under 3	7 C.F.R. § 1.97(b) are statement is filed	, no fee or state d:	ement is required for filing this information
	within three months under § 1.53(d);	s of the filing da	te of a national application other than a CPA
	within three month application; OR	ns of the actual	filing date of the national phase of a PCT
	before the mailing o	of a first substar	tive office action (including after filing of an
Under 3	37 C.F.R. § 1.97(c), ed in 37 C.F.R. § 1.	this information 97(b), but befor	n disclosure statement is filed after the periods e the mailing date of:
	a final rejec	ction under 37 C	C.F.R. 1.113;
	termination	of prosecution	, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);

OR

DT04 Rec'd PCT/PT0 0 1 OCT 2004

	į i	is acco	a notice of allowance under 37 C.F.R. § 1.311; and mpanied by:
	.		the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
	Under 3 date of	37 C.F. the foll	R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
			a final action under 37 C.F.R. § 1.113;
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
•			a notice of allowance under 37 C.F.R. § 1.311;
	AND is	s filed	on or before payment of the issue fee; AND is accompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
Stater	ments Ur	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	d Materia		
		ances	es of materials listed but not attached were cited in benefit (35 U.S.C. § 120) stor application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$	Copi	ies of materials listed but not attached were cited in an international search rt dated June 25, 2003.
		Copi	ies of the materials listed are attached (except for the foregoing).

## Non-Er

<u>Ion-English</u>	Language References
_ 🗆	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
$\boxtimes$	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
	<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> </ul>
	A = document defining the general state of the art O = non-written disclosure
	<ul> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the invention</li> </ul>
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
	D = cited in the application
	L = cited for another reason
	& = publication of member of same patent family
$\boxtimes$	Translation of other relevant information on foreign search report
	In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula 18, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example.
Other Infor	<u>mation</u>
Payment of	Fees Due (If Any):
	heck for \$ covering the fee identified above is attached.
1 1 2 2 0.	······································

Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.

11510046

DT04 Rec'd PCT/PTO 0 1 OCT 2004

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit  $\boxtimes$ Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,


Anthony J/Zelano, Reg. No. 27,969 Attorney/Agent for Applicants


MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza l 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2925

Date: October 1, 2004

AJZ:ssr





Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PT	0		Complete if Known		
Gabanan				Application Number	USNP of PCT/EP03/02349	
INFO	RMATION	DISC	LOSURE	Filing Date	7 March 2003 (07.03.2003)	
	EMENT B			First Named Inventor	Bertram CEZANNE et al.	
SIAI	CIAICIAI D	יואוי	Liorati	Group Art Unit	unknown	
	(use as many sh	eets as n	ecessary)	Examiner Name	unknown	
Sheet	1	of	1	Attorney Docket Number	MERCK-2925	
Sileet j	1 '	1 " 1_				

U.S. PATENT DOCUMENTS							
Examiner Initials *	Cite No.¹	U.S. Patent Docum	ent Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document  MM-DD-YYYY		
mais	001	4,556,674		LABORATOIRES JAQUES	12-03-1985		
	002	6,545,055		ZHU ET AL.	04-08-2003		
	-						
	-						
	-						
		<u> </u>					

				FOREIG	N PATENT DOCUMENTS		Pages, Columns, Lines,	
Examiner	Cite No.1	Office <sup>3</sup>	Foreign Patent Docum Number <sup>4</sup>	ment Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
Hillais	003	WO	0071493	T	COR THERAPEUTICS	11-30-2000		002
	004	DE	10027025		MERCK PATENT	12-06-2001		
	005	wo	0071509	1	COR THERAPEUTICS	11-30-2000		
	006	DE	10102322		MERCK PATENT	07-25-2002		ļ
· · · · · ·								
							<u></u>	<u> </u>

Examiner Signature	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.